MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12185-022-03435-4

Медицинская библиотека · International journal of hematology · 2022

Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study.

Ono Takaaki, Hino Masayuki, Matsumura Itaru, Fujisawa Shin, Ishizawa Kenichi, Sakaida Emiko, Sekiguchi Naohiro, Ono Chiho, Aizawa Mana, Tanetsugu Yusuke, Koide Yuichiro, Takahashi Naoto

Клиническое исследование II фазыСтатьяПеревод пока не подготовлен

Аннотация

Bosutinib has been evaluated for treatment of chronic-phase chronic myeloid leukemia (CP-CML) in several clinical studies, including in Japan. This open-label, single-arm, phase 2 study evaluated the efficacy and safety of bosutinib at a starting dose of 400 mg once daily in Japanese patients (n = 60) with newly diagnosed CP-CML. The minimum follow-up period was 3 years and median duration of treatment was 35.9 months. At study completion, 60% of patients were still on treatment. Cumulative rates of major molecular response (MMR), molecular response4 (MR4), and MR4.5 at any time were 70.0%, 53.3%, and 48.3%, respectively. No patient who achieved MMR or MR4 had a confirmed loss of response. No patient experienced on-treatment transformation to accelerated/blast phase or died within 28 days of the last bosutinib dose. Any-grade treatment-emergent adverse events (TEAEs) occurred in 100% (grade ≥ 3: 81.7%) of patients. The most common TEAEs were diarrhea (86.7%), increased alanine aminotransferase (55.0%), and increased aspartate aminotransferase (46.7%). No new safety signals emerged during the follow-up period. Bosutinib continues to demonstrate a favorable benefit/risk profile and is an important treatment option for Japanese patients with newly diagnosed CP-CML. Optimal management of TEAEs during initial treatment with bosutinib should be prioritized.Trial Registration: ClinicalTrials.gov ID: NCT03128411.

Для цитирования: Ono Takaaki, Hino Masayuki, Matsumura Itaru, Fujisawa Shin, Ishizawa Kenichi, Sakaida Emiko, Sekiguchi Naohiro, Ono Chiho, Aizawa Mana, Tanetsugu Yusuke, Koide Yuichiro, Takahashi Naoto. Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study.. International journal of hematology. 2022. DOI: 10.1007/s12185-022-03435-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.